IE922176A1 - Phospholipid composition - Google Patents

Phospholipid composition

Info

Publication number
IE922176A1
IE922176A1 IE217692A IE922176A IE922176A1 IE 922176 A1 IE922176 A1 IE 922176A1 IE 217692 A IE217692 A IE 217692A IE 922176 A IE922176 A IE 922176A IE 922176 A1 IE922176 A1 IE 922176A1
Authority
IE
Ireland
Prior art keywords
composition
phospholipid
phospholipid composition
phosphatidylcholine
process according
Prior art date
Application number
IE217692A
Inventor
Dr Rainer Losch
Dr Bernd-Rainer Guenther
Joerg Hager
Original Assignee
Rhone Poulenc Rorer Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4219715A external-priority patent/DE4219715C2/en
Application filed by Rhone Poulenc Rorer Gmbh filed Critical Rhone Poulenc Rorer Gmbh
Publication of IE922176A1 publication Critical patent/IE922176A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23JPROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00Phosphatide compositions for foodstuffs, e.g. lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216Solid or semisolid forms
    • A61K8/022Powders; Compacted Powders
    • A61K8/0225Granulated powders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55Phosphorus compounds
    • A61K8/553Phospholipids, e.g. lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/731Cellulose; Quaternized cellulose derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Packages (AREA)
  • Fats And Perfumes (AREA)

Abstract

A powdered or granulated phospholipid compsn. (I) with phosphatidylcholine content at least 80 wt.%, is free from additives. (I) is pref. crystalline, with crystal size 18-0.07mm (6-0.5mm), and with more than 80 (more than 90) wt.% of crystalline phosphatidylcholine components. Esp., it contains 90-96 wt.% of phosphatidylcholine and 0-6% of lysophosphatidylcholine. (I) is prepd. by grinding the phospholipid compsn. with cooling, at below -50 deg.C, opt. after storage at between +5 and -60 deg.C (esp. between 10 and -30 deg.C), partic. for 1-150 (30-70) days. Grinding and/or storage are under an inert gas, esp. N2, CO2 and/or a noble gas. The phospholipid compsn. has been isolated from soya lecithin and contains 90-96 wt.% of phosphatidylcholine. After storage and before grinding, the temp. is brought to room temp. (I) is stored at below 10 (1-6) deg.C, pref. under an inert gas.

Description

This invention relates to a phospholipid composition with the characteristics of the main definition of claim 1 and to a process for the manufacture of such a phospholipid compos20 ition.
Phospholipids occur in both animal and vegetable matter and have to be isolated from these. The main sources are eggs, soybeans, oil seeds and oil fruit, such as coconut copra, palm kernels, groundnuts, rape, sunflower seeds, oil palms and olives.
Phospholipids are isolated from vegetable products by degumming the corresponding vegetable oil with, for example, a small quantity of steam or water. The phospholipid composition produced, also known as lecithin sludge, generally contains ca. 8 to 59% by weight phospholipids and is dried by various methods to yield crude lecithin on drying.
Depending on the initial lecithin sludge used in each case this crude lecithin will have a different chemical composition. Thus according to Weber E.J.; J.A. O.C.S. 58 898 (1981) the most important crude lecithin, soy (soybean) lecithin, is composed, after drying, of ca.: Triglycerides 34.2% phosphatidylcholine 19.1% Diglycerides 0.4% lysophosphatidylcholine 0.7% Free fatty acids 0.4% phosphatidylethanolamine 8.6% 10 Other neutral lipids 0.8% phosphatidylinositol 8.8% Glycolipids 6.5% phosphatidic acid 4.2% Carbohydrate 6.7% N-acy1phosphatidy1- ethanolamine 1.0% 15 others 8.6% Neutral lipids, such as, for example, triglycerides, diglycerides and the like, can be removed from the crude lecithin by deoiling with acetone. The deoiled crude lecithin, also referred to as pure lecithin, is a solid powder capable of being poured, which is available commercially as lecithin granules. The phosphatidylcholine content of pure lecithin lies between ca. 25% by weight and 30% by weight.
The phosphatidylcholine in crude lecithin or pure lecithin can be enriched by known processes. Preferably according to the processes described in European Patents 00 54 770 or 00 54 769. Hereby the crude lecithin is extracted with alcohol. The alcohol-soluble extraction phase is then chromatographed on silicon dioxide at elevated temperatures. On account of its high phosphatidylcholine content the phospholipid composition resulting from the aforesaid process is used for pharmaceutical, cosmetic and dietetic applications. However it exhibits the disadvantage that it is paste-like or waxy depending on its chemical composition. The further processing of this product is often accompanied by considerable problems on account of its consistency which makes it difficult to dose and causes it to stick to the inside walls of vessels, so that the residues remaining in the vessels make frequent and expensive cleaning of the vessels necessary.
In order to eliminate the aforesaid disadvantages in the handling of phospholipid compositions containing large pro10 portions of phosphatidylcholine attempts have already been made to process these products in such a manner that powdered or granule-like high purity lecithins or specific high purity phospholipids are formed.
Thus German Patent 973 741 proposes deoiling crude lecithin with a suitable solvent, for example acetone, separating the deoiled lecithin from the oil extract, then loosening the separated lecithin and drying it as a thin layer. Thereafter the deoiled lecithin can be separated from the layer support used in the form of flocks or leaflets. However it is unlikely that such a process could be carried out nowadays at an economically acceptable cost. Furthermore the phosphatidylcholine content of 30% is too low for the applications described above.
Processes involving the use of additives are also known (US patents 20 57 695 and 30 12 888).
A similar process has been proposed in German patent 38 26 946. Here a special sugar mixture (palatinit) is employed as an additive during the manufacture of the high purity phospholipid composition in order to yield powdered or granulated high purity specific phospholipids or phospholipid compositions .
However the aforesaid known methods possess the disadvantage that additional effort is involved, namely that it is necessary to add and work in an additive. Furthermore the phospholipid compositions prepared by the known methods are only of very restricted application on account of their relatively low phosphatidylcholine concentrations.
The present invention is intended to make available a phospholipid composition and a process for manufacturing such a phospholipid composition, that is particularly simple to carry out and leads to products which are stable on storage.
This intention is fulfilled by a phospholipid composition with the characteristics of patent claim 1 and by a process with the characteristics of patent claim 7.
The phospholipid composition according to the invention with a phosphatidylcholine content of at least 80% by weight takes the form of a powdered or granulated composition and is, hence, free from additives of any sort.
The powdered or granulated phospholipid composition according to the invention exhibits a range of advantages. Thus it is particularly easy to handle on account of its granule25 like or powdered consistency, so that the disadvantages described for the state of the art do not occur. Unexpectedly it was also found that the powdered or granule-like consistency is also maintained when the processing temperature of the powdered or granule-like composition rises to a temperature of about 30 °C. The phospholipid composition also possesses long storage stability of up to several years without any changes occurring in the chemical or physical structure. This is particularly the case if the phospholipid composition is stored at a temperature below 10 °C, preferably at a temperature between 1 °C and 6 °C, preferably under an inert gas.
The aforesaid advantages of the phospholipid composition 5 according to the invention mean that this composition is very readily applied to the manufacture of appropriate finished products, such as, for example, cosmetics, dietetic preparations or pharmaceutical preparations. This is on account of the fact that such powdered or granule-like compositions are particularly simply dosed and can be weighed out with great accuracy and reproducibility, which is not possible in the case of highly viscous or paste-like products. On account of the absence of additives (solidifiers) the composition according to the invention can also be applied where the known phospholipid compositions cannot be used on account of the additives they contain and/or their low phosphatidylcholine content, that is, in particular, for pharmaceutical products.
A particularly suitable embodiment of the composition according to the invention involves the composition according to the invention that, as has already been described, contains at least 80% by weight phosphatidylcholine, being predominantly crystalline. Especially when the composition according to the invention contains more than 80% by weight, and preferably more than 90%, crystalline phosphatidylcholine components, it is found that such a composition particularly possesses the aforesaid advantages that have been described in detail above. In other words such a composition according to the invention contains at least 64% by weight and preferably 72% by weight crystalline phosphatidylcholine components on an absolute basis. Unexpectedly it could be demonstrated that such a composition according to the invention, that preferably was composed primarily of crystalline components, is excellently dispersible in water, which, for example, considerably eases the manufacture of appropriate aqueous suspensions of cosmetic, dietetic or pharmaceutical preparations. The aforesaid ready dispersibility is unknown for phospholipid compositions according to the state of the art which is attributable to the fact that such known compositions are predominantly amorphous in nature.
A further embodiment of the composition according to the 10 invention proposes that this possesses a concentration of at least 90% by weight phosphatidylcholine.
Another embodiment of the aforesaid composition contains the composition according to the invention 93% by wt. ± 3% by wt. phosphatidylcholine and 3% by wt. + 3% by wt. lysophosphatidylcholine, whereby the aforesaid values have been checked by a known 20 quantitative thin-layer chromatographic analysis method.
Such a composition preferably does not contain any phosphatidylethanolamine and/or any phosphatidylinositol.
With respect to the particle size of the phospholipid com25 position according to the invention it may be said that this is adjusted according to the particular field of application. The phospholipid composition is preferably comminuted to a particle or crystallite size between 18 mm and 0.07 mm, particularly to a particle size between 6 mm to 0.5 mm.
The present invention also applies to a process for the preparation of the aforesaid phospholipid compositions.
The process according to the invention for the preparation of the powdered or granulated phospholipid composition starts out with an appropriate phospholipid composition, that, depending on its composition, possesses a pasty to waxy consistency under the usual conditions of storage. In this connection this phospholipid composition is comminuted to the desired powder or granule size while cooled to a temperature below - 50 °C.
Unexpectedly it could be established that phospholipid com10 positions could be comminuted without problems under these temperatures without the need for admixture of the solidifying agents required in the known methods. In addition compositions that have been comminuted in this manner and that contain at least 80% by weight phosphatidylcholine are stable up to a temperature of 30 °C for several months and years so that chemical and physical changes do not occur.
A further specially favoured embodiment of the process according to the invention provides for the storage of the phospholipid composition at temperatures between + 5 °C and - 60 °C, particularly at temperatures between - 10 °C and - 30 °C before comminution. Whereby the storage time varies between one day and 150 days, preferably between 30 days and 70 days depending on the storage temperature chosen. A phospholipid composition stored in the aforesaid manner can be comminuted to the initially mentioned particle size of 18 mm to 0.07 mm, preferably of 6 mm to 0.5 mm within a very short time.
Depending on the particular phospholipid composition employed a further method of execution of the process according to the invention involves the comminution and/or storage of the particular phospholipid composition at the aforesaid temperatures and for the aforesaid storage time under inert gas. In particular the inert gas can be liquid nitrogen, carbon dioxide, a noble gas or a mixture of the aforesaid gases. This method of operation under inert gas prevents an undesired oxidative modification of the phospholipid compos5 ition.
As already described above various highly purified phospholipid compositions isolated from natural products can be employed as starting materials for the process according to the invention, provided that they contain at least 80% by weight phosphatidylcholine. Such a composition can be isolated preferably from eggs, oil seeds and oil fruit and particularly soybean by the known procedures. However, it is particularly suitable when a soy (soybean) lecithin whose phosphatidylcholine content is at least 90% by weight and preferably 93 ± 3% by weight is employed in the process according to the invention. Such a high purity soy lecithin can, for example, be isolated by the methods as they are described in the European patents 0 054 770 and 0 054 769.
In order to be able to store the powdered or granulated product prepared by the process according to the invention over a long period of time without chemical or physical change a further embodiment of the process according to the invention envisages storage at a temperature below 10 °C and preferably between 1 °C and 6 °C.
A further improvement in the storage stability is achieved if the phospholipid composition is sealed into airtight sachets, for example of appropriate aluminium foil, and stored at the aforesaid temperatures.
A further embodiment of the aforesaid process envisages displacing the air contained in the sachets after they have been filled with an inert gas, for example, nitrogen, a noble gas, carbon dioxide or a mixture of the aforesaid gases .
As already described above the powdered or granulated phospholipid composition according to the invention is very easy to handle and can be employed for various purposes. Thus, for example, such a powdered or granulated phospholipid composition can be used as solution promoter, natural sur10 factant and/or liposome former in cosmetic products and especially in pharmaceutical products, since the phospholipid composition according to the invention is free from solidifying agents.
Advantageous further embodiments of the phospholipid composition according to the invention and the process according to the invention are set out in the subsidiary claims.
The process according to the invention is further illus20 trated by the examples that follow.
Example 1 300 kg of a phospholipid composition containing 93% ± 3% by weight phosphatidylcholine that, for example, had been isolated from soybeans according to the processes described in European patents 00 54 770 or 00 54 769 was stored at - 20 °C for 2 months. Immediatley before the phospholipid composition was comminuted it was brought to room tempera30 ture (17 °C to 21 °C). Then the composition was comminuted in a conventional cold milling plant with liquid nitrogen cooling and sealed portionwise in aluminium sachets under inert gase (nitrogen). The product that had been so packed was stored at + 4 °C.
Stability tests revealed that the product retained its powdered or granulated form at temperatures up to + 30 °C.
Immediately before such a product is processed it is warmed 5 to room temperature to avoid the condensation of water onto the comminuted product.
Example 2 jAs described above 100 kg of the aforesaid composition were comminuted in the cold. However in contrast to example 1 th storage time before comminution was one month at -17 °C.
Stability tests revealed that there was no change in consis tency even after storage for 12 weeks at room temperature (20 °C ± 2 °C) after comminution and packing.
The powdered or granulated phospholipid composition so isolated had the following chemical composition: Phosphatidylcholine Phophatidylethanolamine Phosphatidylinositol Lysophosphatidylcholine Water Triglycerides (oils) 94.2% by wt. not detectable not detectable 3.7% by wt. 1.3% by wt. 0.8% by wt.
Example 3 As previously described in example 1, 300 kg phospholipid composition were comminuted together with 150 kg carbon dioxide granules. Whereby the other conditions corresponded to those described in example 1. Π Stability tests revealed that the composition prepared according to example 3, which contained the aforesaid high phosphatidylcholine content, also remained unchanged in consistency even on storage for six months after comminution .

Claims (14)

1. Phospholipid composition with a phosphatidylcholine content of at least 80% by weight wherein the powdered or granulated composition is free from additives. 5
2. Composition according to claim 1 wherein the composition is predominantly crystalline.
3. Composition according to claim 2 wherein the composition contains at least more than 80% by weight, preferably more 10 than 90% by weight crystalline phosphatidylcholine components .
4. Composition according to one of the preceding claims wherein it possesses a phosphatidylcholine content of at 15 least 90%.
5. Composition according to one of the preceding claims wherein it contains 93 ± 3% by wt. phosphatidylcholine and 5 3 ± 3% by wt. lysophosphatidylcholine.
6. Composition according to one of the preceding claims wherein it has a particle or crystallite size between 18 mm and 0.07 mm, preferably between 6 mm and 0.5 mm.
7. A process for the manufacture of the phospholipid composition according to one of claims 1 to 6, wherein the phospholipid composition is comminuted after cooling to a temperature below - 50 °C.
8. A process according to claim 7 wherein the phospholipid composition is stored at temperatures between + 5 °C and - 60 °C, preferably between - 10 °C and - 30 °C before being comminuted .
9. A process according to claim 8 wherein the phospholipid composition is stored for between one day and 150 days, preferably between 30 days and 70 days. 25 10. A process according to one of claims 7 to 9 wherein the comminution and/or the storage of the phospholipid composition is carried out under inert gas. 11. A process according to claim 10 wherein the inert gas is 30 nitrogen, carbon dioxide, a noble gas or a mixture of these gases . Μ 12. A process according to one of claims 7 to 11 wherein a phospholipid composition is chosen that is isolated from soy (soybean) lecithin and contains 93 ± 3% by weight phosphatidylcholine . 13. A process according to claim 8 or 9 wherein the phospholipid composition is returned to room temperature after storage and before comminution.
10. 14. A process according to one of claims 7 to 13 wherein the powdered or granulated phospholipid composition is stored at a temperature lower than 10 °C, preferably at a temperature between 1 °C and 6 °C.
11. 15 15. A process according to claim 14 wherein the powdered or granulated phospholipid composition is stored under inert gas .
12. 16. A phospholipid composition substantially as described herein with reference to the Examples.
13. 17. A process for the manufacture of a phospholipid composition substantially as described herein with reference to the Examples.
14. 18. A phospholipid composition whenever prepared by a process as claimed in any of claims 7 to 15 or 17.
IE217692A 1991-07-05 1992-07-03 Phospholipid composition IE922176A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4122300 1991-07-05
DE4219715A DE4219715C2 (en) 1991-07-05 1992-06-17 Phospholipidic composition

Publications (1)

Publication Number Publication Date
IE922176A1 true IE922176A1 (en) 1993-01-13

Family

ID=25905244

Family Applications (1)

Application Number Title Priority Date Filing Date
IE217692A IE922176A1 (en) 1991-07-05 1992-07-03 Phospholipid composition

Country Status (8)

Country Link
EP (1) EP0521398B1 (en)
JP (2) JP3213391B2 (en)
AT (1) ATE172600T1 (en)
CA (1) CA2073096C (en)
DE (1) DE59209542D1 (en)
DK (1) DK0521398T3 (en)
ES (1) ES2122975T3 (en)
IE (1) IE922176A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635206A (en) * 1994-01-20 1997-06-03 Hoffmann-La Roche Inc. Process for liposomes or proliposomes
DE19859455A1 (en) * 1998-12-22 2000-07-06 Dianorm G Maierhofer Gmbh Disperse system as a skin care product
US20030206881A1 (en) * 2001-05-31 2003-11-06 Peter Fussbroich Phospholipidic composition as well as the use thereof
DE10340741A1 (en) * 2003-09-04 2005-03-31 Degussa Food Ingredients Gmbh Phospholipid-based formulation
US8535750B2 (en) 2005-05-17 2013-09-17 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them
EP2387391B1 (en) 2009-07-24 2017-01-11 MIKA Pharma Gesellschaft für die Entwicklung und Vermarktung pharmazeutischer Produkte mbH Method for developing a liquid composition to be applied to the skin as a foam and a composition that can be applied topically
DE102013004199A1 (en) * 2012-05-15 2013-11-21 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Pharmaceutical composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2948607A1 (en) * 1979-12-03 1981-06-11 Chemische Fabrik Dr. Meyer-Castens & Co Nfg., 2000 Hamburg METHOD FOR PRODUCING A LECITHIN-BASED EMULSIFIER
JPS58164513A (en) * 1982-03-25 1983-09-29 Teijin Ltd Active substance on surface of lung and its preparation
JPS5928456A (en) * 1982-08-10 1984-02-15 Nichibei Zoki Kk Nutrient assistant food prepared from brain of food animal
JPS6310718A (en) * 1986-07-02 1988-01-18 Tokyo Tanabe Co Ltd Production of pulmonary surface active substance preparation
JPH02172994A (en) * 1988-12-24 1990-07-04 Nippon Oil & Fats Co Ltd Production of powdered egg yolk lecithin

Also Published As

Publication number Publication date
JP2002037794A (en) 2002-02-06
DE59209542D1 (en) 1998-12-03
JPH05252875A (en) 1993-10-05
CA2073096A1 (en) 1993-01-06
ATE172600T1 (en) 1998-11-15
CA2073096C (en) 1999-01-19
EP0521398A2 (en) 1993-01-07
ES2122975T3 (en) 1999-01-01
EP0521398A3 (en) 1993-03-31
EP0521398B1 (en) 1998-10-28
JP3213391B2 (en) 2001-10-02
DK0521398T3 (en) 1999-07-05
JP3500130B2 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
US5310734A (en) Phospholipid composition
US5438044A (en) Phospholipid composition
US4229360A (en) Process for the dehydration of a colloidal dispersion of lipsomes
US4814161A (en) Drug-containing chlorofluorocarbon aerosol propellent formulations
EP0229652B1 (en) Stabilized tocopherol in dry, particulate, free-flowing form
CA1205383A (en) Method of encapsulating biologically active materials in multilamellar lipid vesicles (mlv)
EP0725620B1 (en) Non-sweating lipsticks
US4849132A (en) Surfactant composition having improved functions
CA2062854A1 (en) Pharmaceutical aerosol formulations
JPH024899A (en) Oxidation inhibitor
JPH0753661B2 (en) Pro-liposome composition and method of making an aqueous dispersion of liposomes
JPH06287108A (en) Anhydrous make-up goods composition containing fat phase and make-up processing method using said composition
JPH08500972A (en) How to remove oil from raw lecithin
CA2073096C (en) Phospholipid composition
WO2005077419A1 (en) Soft capsule preparation
EP0242812A1 (en) Use of glycofurol in liquefying pharmaceutical preparations for filling soft gelatin capsules
US6288130B1 (en) Oil-free glycerophospholipid formulations and method for the production thereof
CA2388169A1 (en) Phospholipid composition and use of same
EP1659878A2 (en) Formulation based on phospholipids
JP2005290308A (en) Method for producing phospholipid composition, and pharmaceutical composition, cosmetic composition or food composition using the same
JPH06279467A (en) Phospholipid composition
JP3061777B2 (en) Egg yolk lecithin mixture
EP0950392B1 (en) Non-sweating lipsticks
US4022923A (en) Frozen garlic and method of producing the same
JPH0570793A (en) Granular lipid composition

Legal Events

Date Code Title Description
MM4A Patent lapsed